The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...
The risk for severe adverse events for patients with chronic obstructive pulmonary disease was significantly lower among those treated with glycopyrronium/indacaterol ...
LAMAs were found to be safe and effective in the treatment of COPD and have been recommended by international clinical guidelines for the management of symptoms in COPD. A population-based cohort ...
Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...
RIDGEFIELD, Conn. and NORWALK, Conn., Nov. 17, 2022 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals Inc. welcomes the updated 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) ...
SAN FRANCISCO -- Patients with chronic obstructive pulmonary disease (COPD) who changed treatment from so-called triple therapy to a two-drug product omitting the inhaled corticosteroid (ICS) ...
Most patients with chronic obstructive pulmonary disease (COPD) remain untreated after diagnosis, leading to frequent exacerbations. After COPD diagnosis, prompt and effective single or dual ...
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results